Creative Planning Makes New Investment in USANA Health Sciences, Inc. (NYSE:USNA)

Creative Planning bought a new position in shares of USANA Health Sciences, Inc. (NYSE:USNA) during the third quarter, according to its most recent filing with the SEC. The fund bought 10,398 shares of the company’s stock, valued at approximately $394,000. Creative Planning owned 0.05% of USANA Health Sciences at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BOKF NA lifted its position in USANA Health Sciences by 274.5% in the first quarter. BOKF NA now owns 2,771 shares of the company’s stock valued at $133,000 after purchasing an additional 2,031 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of USANA Health Sciences by 9.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company’s stock valued at $284,000 after buying an additional 494 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of USANA Health Sciences during the second quarter valued at $340,000. Exchange Traded Concepts LLC increased its stake in shares of USANA Health Sciences by 4.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 7,709 shares of the company’s stock worth $292,000 after purchasing an additional 322 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System lifted its stake in shares of USANA Health Sciences by 22.7% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 8,430 shares of the company’s stock valued at $409,000 after buying an additional 1,560 shares in the last quarter. 54.25% of the stock is currently owned by institutional investors.

Insider Transactions at USANA Health Sciences

In related news, insider Paul A. Jones sold 6,266 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total transaction of $240,489.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Gilbert A. Fuller sold 675 shares of the stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $37.71, for a total value of $25,454.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Paul A. Jones sold 6,266 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total transaction of $240,489.08. The disclosure for this sale can be found here. Corporate insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on USNA. StockNews.com lowered shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th. DA Davidson reduced their price target on USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating for the company in a research report on Wednesday, October 23rd.

USANA Health Sciences Stock Up 0.4 %

Shares of USANA Health Sciences stock opened at $40.50 on Friday. USANA Health Sciences, Inc. has a twelve month low of $34.15 and a twelve month high of $54.81. The business has a 50-day moving average price of $37.52 and a 200 day moving average price of $42.06. The firm has a market cap of $771.61 million, a PE ratio of 14.31, a P/E/G ratio of 1.29 and a beta of 0.89.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.07. The business had revenue of $200.22 million for the quarter, compared to analysts’ expectations of $208.45 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. During the same period in the previous year, the firm posted $0.59 EPS. On average, sell-side analysts expect that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.